Results 161 to 170 of about 43,016 (203)

Early effects of a novel 5-HT₄ agonist (PF-04995274) and the SSRI citalopram on emotional cognition in unmedicated depression: the RESTAND study

Gillespie A, de Cates A, Scaife J, Blandhol M, Martens M, Gibson D, Godlewska B, Howard W, Cowen P, Murphy S, Harmer C.   +10 more
europepmc   +1 more source

Understanding antidepressant change patterns in the UK Biobank

Li D, Lo CWH, Lewis CM, Vassos E, Breen G.   +4 more
europepmc   +1 more source

Some of the next articles are maybe not open access.

Related searches:

Citalopram

Human Psychopharmacology: Clinical and Experimental, 2000
Citalopram is a selective serotonin (5-HT) reuptake inhibitor (SSRI) developed by H. Lundbeck A/S in Denmark. It is the most selective serotonin antidepressant with proven efficacy, a favourable pharmacokinetic profile and a low potential for interactions with other concomitant medication.
Andre F., Joubert, Connie, Sánchez, Frank, Larsen   +2 more
openaire   +2 more sources

Citalopram

Reactions Weekly, 2017
John C. Courtney, Efrain Antonio Gonzalez   +1 more
  +6 more sources

Citalopram

DMW - Deutsche Medizinische Wochenschrift, 2003
A, El-Armouche, O, Zolk, T, Eschenhagen
  +5 more sources

citalopram

Reactions Weekly, 2009
Guillaume Chevrel, Virginie Dessus
  +4 more sources

Citalopram

Reactions Weekly, 2004
  +5 more sources

Citalopram

Reactions Weekly, 2011
  +5 more sources